Cargando…
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
Spot baseline urinary monoamine assays have been used in medicine for over 50 years as a screening test for monoamine-secreting tumors, such as pheochromocytoma and carcinoid syndrome. In these disease states, when the result of a spot baseline monoamine assay is above the specific value set by the...
Autores principales: | Hinz, Marty, Stein, Alvin, Uncini, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165907/ https://www.ncbi.nlm.nih.gov/pubmed/21912487 http://dx.doi.org/10.2147/IJNRD.S22783 |
Ejemplares similares
-
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
por: Hinz, Marty, et al.
Publicado: (2011) -
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Retraction]
Publicado: (2021) -
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Expression of Concern]
Publicado: (2020) -
The discrediting of the monoamine hypothesis
por: Hinz, Marty, et al.
Publicado: (2012) -
Monoamine depletion by reuptake inhibitors
por: Hinz, Marty, et al.
Publicado: (2011)